Skip to content
Home/GPs/Cambridge Innovation Capital
Cambridge Innovation Capital

Cambridge Innovation Capital

Cambridge, United Kingdom·Founded 2013··cic.vc

Cambridge Innovation Capital is a Cambridge deep-tech and life-sciences venture firm founded in 2013 to back University of Cambridge ecosystem spin-outs, typically at Series A. It launched in 2013 with GBP 50 million from Invesco Perpetual, Lansdowne Partners, the Cambridge University Endowment Fund, ARM and IP Group, grew its first vehicle to GBP 275 million, closed Fund II at GBP 225 million (USD 300 million) in April 2022, and launched a GBP 100 million Opportunity Fund in February 2025 anchored by Aviva Investors and British Patient Capital. Its manager, Cambridge Innovation Capital Manager Limited, is authorised and regulated by the UK Financial Conduct Authority under firm reference number 918898.

AUM
€702M
Funds
4
vintages 2013–2025
Portfolio
23
Exits
9

Key facts

HQCambridge, United Kingdom
Founded2013
Websitecic.vc

Recent exits

Seldon
Seldon
AI/ML2026 · 6yr hold
Congenica
Congenica
Biotech2025 · 10yr hold
Cytora
Cytora
InsurTech2025 · 8yr hold
PredictImmune
HealthTech2024 · 5yr hold

Coverage notes

4 funds tracked, 32 portfolio companies (23 active · 9 realized). Verified weekly from public filings and deal announcements.

Sector breakdown

32 companies
Biotech
15 · 47%
AI/ML
6 · 19%
Deep Tech
4 · 13%
HealthTech
3 · 9%
MedTech
2 · 6%
Telecom
1 · 3%
InsurTech
1 · 3%

Funds & portfolio

Every fund Cambridge Innovation Capital has raised, with its portfolio companies. Hand-checked from public filings.

4 funds
CIC Opportunity FundVC
2025 · 1yr€100M2 active

Unrealized

2 held
BeyondMath
BeyondMathActive
AI/MLUK· Entry 2026
Trent AI
Trent AIActive
AI/MLUK· Entry 2026
CIC Fund IIIVC
2025 · 1yr€293M0 active

No portfolio companies tracked yet.

CIC Fund IIVC
2022 · 4yr€263M12 active · 2 realized

Unrealized

12 held
Deep TechUK· Entry 2022
BiotechUK· Entry 2023
Epitopea
EpitopeaActive
BiotechUK· Entry 2022
Forefront RF
Forefront RFActive
TelecomUK· Entry 2024
Immutrin
ImmutrinActive
BiotechUK· Entry 2025
Mosaic TX
Mosaic TXActive
BiotechUK· Entry 2023
Nuclera
NucleraActive
BiotechUK· Entry 2024
BiotechUS· Entry 2022
Deep TechUK· Entry 2022
BiotechUK· Entry 2023
BiotechUK· Entry 2025
Unlikely AI
Unlikely AIActive
AI/MLUK· Entry 2022

Realized

2 exits
Congenica
CongenicaExited 2025
BiotechUK· Entry 2015
Trade Saleto
PetMedix
PetMedixExited 2023
BiotechUK· Entry 2020
Trade Saleto
CIC Fund IVC
2013 · 13yr€322M9 active · 7 realized

Unrealized

9 held
BiotechUK· Entry 2016
BiotechUK· Entry 2016
CMR Surgical
CMR SurgicalActive
MedTechUK· Entry 2016
Microbiotica
MicrobioticaActive
BiotechUK· Entry 2016
Deep TechUK· Entry 2014
Riverlane
RiverlaneActive
Deep TechUK· Entry 2017
Secondmind
SecondmindActive
AI/MLUK· Entry 2017
MedTechUK· Entry 2019
BiotechUK· Entry 2016

Realized

7 exits
AbcodiaExited 2022
HealthTechUK· Entry 2015
Trade Saleto
Audio AnalyticExited 2022
AI/MLUK· Entry 2017
Trade Saleto
Cytora
CytoraExited 2025
InsurTechUK· Entry 2017
Trade Saleto
BiotechUK· Entry 2019
Trade Saleto
Inivata
InivataExited 2021
HealthTechUK· Entry 2016
Trade Saleto
PredictImmuneExited 2024
HealthTechUK· Entry 2019
Seldon
SeldonExited 2026
AI/MLUK· Entry 2020
Trade Saleto
Track Cambridge Innovation Capital

Saved GPs appear in your watchlist, one click from your workspace.

About Cambridge Innovation Capital

Cambridge Innovation Capital (CIC) is a UK preferred venture capital investor for the University of Cambridge ecosystem with approximately £600 million of assets under management as of December 2024, headquartered in Cambridge. The firm was founded in 2013 as the strategic partner of the University of Cambridge, anchored in the Cambridge cluster spinout pipeline. CIC remains a partner-owned independent VC platform with exclusive scale-up investor status across Cambridge spinouts.

Investment thesis

CIC deploys capital through three plus active vehicles (Fund I, Fund II, Fund III early-stage £250 million 2025 plus £100 million Opportunity Fund 2025), targeting early-stage and growth venture investments in deep-tech and life sciences spinouts from the Cambridge cluster. The Opportunity Fund enables late-stage follow-ons up to £20 million per round, addressing the UK growth-financing gap that historically constrained Cambridge spinout scale-up. Sector focus spans artificial intelligence, quantum computing, semiconductors, therapeutics, medtech and diagnostics, digital health and genomics. Geographic deployment is anchored on Cambridge ecosystem with broader UK reach.

Recent activity

Recent investments include Pragmatic Semiconductor (chips, 2025), Riverlane (quantum computing, 2024-2025) and commitments to multiple Cambridge spinouts under Fund III (2025). Realised exits across the 2024-2025 period emphasised follow-on rounds over secondary realisations, with gene therapy and biotech exits forming the historical baseline. The platform continues active deployment across the Cambridge spinout pipeline and Opportunity Fund late-stage strategy. Detailed buyer names and multiple data available on Pro at €29/month.

Get the full picture on Cambridge Innovation Capital.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Save this GP to your watchlist
Saved searches that re-run your sourcing filters in one click
Geography breakdown across 2 geographies
Exit buyers and MOIC on every realized deal (Pro)
Export, compare GPs side by side (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Last updated August 2026 · Sourced from public filings · Report an issue